Introduction
Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare tumour that accounts for approximately 0.13-2.7% of all pancreatic tumours and approximately 1-2% of all exocrine pancreatic tumours. [1] [2] [3] [4] [5] [6] Because of their rare recurrence and rare metastasis to other organs, such as the liver or lung, SPNs are considered low-grade malignant tumours. 3, [7] [8] [9] Microscopically, SPNs are usually composed of poorly cohesive monomorphic epithelial cells forming a solid and pseudopapillary structure with hyalinised or myxoid stroma, haemorrhage, necrosis and cholesterol clefts. [1] [2] [3] [4] [5] [6] We recently encountered a case of SPN with a prominent microcystic pattern characterised by anastomotic strands and a pseudocystic and/or microcystic arrangement of uniform tumour cells within myxoid stroma (Figure 1) .
The pathological diagnosis of SPNs with a prominent microcystic pattern can be difficult because of these unusual histological features. To date, it appears that SPNs with a microcystic structure have simply been mentioned in some reports and described as a 'pseudocyst' or 'microcyst', 5, [10] [11] [12] [13] but to our knowledge such a morphological pattern of SPNs has never been described in detail. Histological images of a microcystic or pseudocystic reticular pattern of SPNs have not been demonstrated clearly in previous investigations and textbooks, and because the microcystic pattern of SPNs has not been well documented, the microcystic pattern can cause pathological diagnostic confusion, particularly for inexperienced pathologists.
An endoscopic ultrasound (EUS)-guided needle biopsy or cytology is often performed for the preoperative diagnosis of SPNs. 14, 15 When an EUSguided needle biopsy is performed the microcystic pattern of SPNs can cause diagnostic confusion, especially when the amount of the provided sample is inadequate. When most of the samples obtained show a microcystic pattern, the correct diagnosis of SPN could still be difficult. Here, we focused on the microcystic pattern of SPNs, and our findings demonstrated these tumours' clinicopathological and immunohistochemical features.
Materials and methods
We examined retrospectively a consecutive series of 44 SPNs of the pancreas that had been resected surgically and diagnosed pathologically at Kyushu University, Japanese Red Cross Oita Hospital and Red Cross Matsuyama Hospital between 1999 and 2014. For a comparative study, 10 microcystic-type serous cystadenomas (SCAs) of the pancreas that had been resected and diagnosed at Kyushu University were also investigated. Follow-up information was obtained by reviewing the medical records of the patients and communicating with the physicians and pathologists at each facility. This study was approved by the institutional review board of Kyushu University (no. 28-109).
The histological diagnosis of SPNs was made based on a light microscopic examination of haematoxylin and eosin (H&E)-stained slides and according to the recent World Health Organisation (WHO) classification. 5 On the basis of morphological features, we classified the 44 SPNs into two groups: conventional SPNs (n = 31) and microcystic SPNs (n = 13). For the diagnosis of microcystic SPNs, an area showing the microcystic pattern that was >5% of the total tumour area was required.
SPNs showing essentially only solid and pseudopapillary patterns (i.e. microcystic pattern area <5% of the total tumour area) were considered conventional SPNs. We assessed and compared the following clinicopathological factors in the conventional versus microcystic groups: age, sex, specific symptoms, location, magnetic resonance imaging (MRI) image, cut surface of the tumour, size, 5-year survival, tumour cell morphology, stromal feature, invasion and metastasis. Antigen retrieval was performed by heating tissue sections at 100°C in 0.01 mol/l sodium citrate buffer and 0.01% Tween (pH 6.0) (b-catenin and E-cadherin) or in 0.01 mol/l sodium citrate buffer (pH 6.0) (CD10, CD56, AE1/AE3, FoxL2, inhibin-a) or target retrieval solution (pH 9.0) (WT-1) for 20 min (b-catenin, E-cadherin, CD10, CD56, AE1/AE3, WT-1) or 30 min (FoxL2, inhibin-a) in a microwave oven. The sections were incubated with the primary antibodies at room temperature for 90 min, followed by staining with the secondary antibody.
We used an EnVision FLEX/FLEX+ system (Dako, Tokyo, Japan) for the ER and PgR staining. Sections (3-lm thick) were processed using a heat-mediated antigen retrieval for 45 min at 99°C in Envision Flex Target Retrieval Solution High pH (pH 9.0, code K8024; Dako). After endogenous peroxidase activity was blocked using methanol containing 0.3% hydrogen peroxidase for 30 min, serial sections were stained with rabbit monoclonal anti-ER and mouse monoclonal anti-PgR antibodies. Mouse-linker was used for the PgR stain. Slides were processed by the EnVision Flex/HPR system (code K8024; Dako).
We determined the percentage of immunoreactive cells with unequivocal staining intensity in the most representative areas (conventional SPNs: solid-pseudopapillary area, microcystic SPNs: microcystic area and solid pseudopapillary area). The criteria for positive immunoreactivity were as follows: b-catenin, E-cadherin, WT-1: nuclear staining in >5% of all tumour cells 16 ; CD10: cytoplasmic or membranous staining in >5% of tumour cells 17 ; CD56: membranous staining in >5% of tumour cells 17 ; AE1/AE3: cytoplasmic staining in >5% of tumour cells 17 ; FoxL2: nuclear staining in >5% of all tumour cells 17 ; and inhibin-a: cytoplasmic staining in >5% of tumour cells. 17 PgR and ER The Allred scoring system was used for ER, PR staining. [18] [19] [20] The proportion of positively stained cells was rated as follows: 0, no cells stained positive; 1, between 0% and 1% positive; 2, between 1% and 10% positive; 3, between 10% and 33% positive; 4, between 33% and 66% positive; and 5, between 66% and 100% positive. In addition to the proportion score, an intensity score was made on the basis of the average intensity of staining: 0, negative; 1, weak (faint staining can be detected only by high . The intensity score and the proportion score were added to obtain the total score. Total scores greater than 3 were interpreted as positive.
M U C I N H I S T O C H E M I S T R Y
We performed mucin histochemistry for the property evaluation of mucin in the microcyst and hyalinised myxoid stroma of the solid pseudopapillary area of all of the SPNs; mucin histochemistry of Alcian blue pH 2.5 and of Alcian blue pH 2.5 with hyaluronidase digestion were performed. The positivity of mucin histochemistry was evaluated in the most representative areas of the SPNs (n = 44).
S T A T I S T I C A L A N A L Y S E S
Statistical analyses were performed with JMP software version 11 (SAS Institute, Cary, NC, USA). Categorical variables were compared by the v 2 test or Fisher's exact test. A P-value <0.05 was considered significant.
Results

C L I N I C O P A T H O L O G I C A L C H A R A C T E R I S T I C S
The clinicopathological characteristics of the 44 SPNs are summarised in Table 1 . Representative images of microcystic SPNs are provided in Figure 1A -C. In these neoplasms, the microcystic areas occupied 5-95% of the total tumour area (median: 41.1%, range: 5-95%). A solid pseudopapillary structure and poorly cohesive monomorphic tumour cells with round-tooval nuclei were characteristic features of the conventional SPNs, and these features were also recognised in all the microcystic SPNs ( Figure 1D ).
The frequency of clear cell changes in the microcystic SPNs was significantly higher than that in the conventional SPNs (84.6% versus 48.3%; P = 0.027) ( Figure 1E ). The frequency of hyalinised stroma (Figure 1F ) in the microcystic SPNs was significantly higher than that in the conventional SPNs (92.3% versus 9.7%; P < 0.001). The frequency of haemorrhage was significantly lower in the microcystic SPNs than in the conventional SPNs (76.9% versus 96.8%; P = 0.033).
The pre-operative EUS-guided biopsy was performed in only six cases, including one microcystic SPN. Five cases of SPNs including one microcystic SPN were diagnosed correctly as such. The remaining one case of conventional SPN was misdiagnosed as neuroendocrine tumour.
I M M U N O H I S T O C H E M I S T R Y
Representative images and results of immunohistochemistry for b-catenin, E-cadherin, CD10, CD56, PgR, ER, AE1/AE3, WT-1, FoxL2 and inhibin-a are provided in Table 2 and Figure 2 . We made the following comparisons: conventional SPNs versus the microcystic area of microcystic SPNs (Table 2) , conventional SPNs versus the conventional area of microcystic SPNs (Table 2) , microcystic area versus the conventional area in the microcystic SPNs (Table 2 ) and the microcystic area of the microcystic SPNs versus the microcystic-type SCAs (Table 2 ).
In our comparison of the conventional SPNs versus the microcystic area of the microcystic SPNs, the microcystic area of the microcystic SPNs showed significantly lower expressions of CD56 (P = 0.0085) and CD10 (P < 0.001) compared to the conventional SPNs (Table 2, Figure 2 ). The nuclear expressions of b-catenin and E-cadherin consistently labelled the tumour nuclei in both the microcystic SPNs (13 of 13 cases) and the conventional SPNs (31 of 31 cases) (Figure 2A,B,G,H) . Figure 2E,K) . FoxL2, WT-1 and inhibin-a were completely negative in both the microcystic SPNs and the conventional SPNs.
Our comparison of the conventional SPNs versus the conventional area of the microcystic SPNs revealed that the conventional area of the microcystic SPNs showed significantly lower expression of CD56 (P = 0.0085) and CD10 (P < 0.0042) compared to the conventional SPNs (Table 2 ). In the microcystic SPNs, the CD10 expression was occasionally positive in conventional areas, despite the negative CD10 expression in microcystic areas. There were no significant differences in other antibodies.
In the comparison of the microcystic area versus the conventional area in the microcystic SPNs, the CD10 expression of the microcystic areas was significantly lower than that of the conventional areas (P = 0.0052) ( Table 2 ). There were no significant changes in other antibodies.
We compared the immunohistochemical features of the microcystic areas of the microcystic SPNs and microcystic-type SCAs (which resembled microcystic SPNs histologically) ( Table 2 ). All 13 of the microcystic SPNs showed nuclear expressions of betacatenin and E-cadherin, but these expressions were completely absent in the microcystic-type SCAs. The microcystic SPNs showed significantly higher expressions of CD56 and PgR compared to the microcystic-type SCAs. The microcystic SPNs showed a significantly lower expression of AE1/AE3 and inhibin-a compared to the microcystic-type SCAs. There was no homology between the microcystic SPNs and the microcystic-type SCAs, particularly in the expression of b-catenin and E-cadherin.
M U C I N H I S T O C H E M I S T R Y
The mucin in the microcysts of the microcystic SPNs was positive for Alcian blue (100%, 13 of 13), and the positivity was diminished after hyaluronidase digestion (92.3%, 12 of 13; Figure 3 , Table 3 ). Hyalinised and myxoid stroma of the solid pseudopapillary area in the microcystic SPNs was positive for Alcian blue (92.3%, 12 of 13), and the positivity was diminished after hyaluronidase digestion (100%, 12 of 12; Figure 3 , Table 3 . The hyalinised and myxoid stroma of conventional SPNs was positive for Alcian blue (51.6%, 16 of 31), and the positivity was diminished after hyaluronidase digestion (100%, 16 of/16; Figure 3, Table 3 ).
The Alcian blue positivity of the microcystic area of the microcystic SPNs was significantly higher than that of the solid pseudopapillary area of the conventional SPNs (P = 0.0015; Table 3 ). The Alcian blue positivity of the solid pseudopapillary areas of the microcystic SPNs was significantly higher than that of the solid pseudopapillary areas of the conventional SPNs (P = 0.0151; Table 3 ). These findings indicated that the mucin in the microcysts and the hyalinised and myxoid stroma of the microcystic SPNs and the conventional SPNs contained abundant glycosaminoglycans such as hyaluronan. 
Discussion
The description of the microcystic pattern in SPNs is limited to a single case report by Kakihara et al. 11 As a morphological pattern other than the solid pseudopapillary pattern, the term 'pseudocystic' is used in the WHO blue book. 5 However, a pseudocystic or microcystic pattern of SPN has not been well illustrated in the existing textbooks. To the best of our knowledge, there has been no investigation focusing on the microcystic pattern of SPN, and this may lead to diagnostic confusion. In the present study, we identified 13 microcystic SPNs in a consecutive series of 44 SPNs (29.5%, 13 of 44), and thus the microcystic pattern is not infrequently observed in SPNs.
The clinicopathological and immunohistochemical features of the microcystic SPNs in this study were generally similar to those of the conventional SPNs.
In this context, the microcystic pattern is on the morphological spectrum of pancreatic SPNs. Based on this finding, when pancreatic tumours with a microcystic pattern are observed, it is important for surgical pathologists to include SPNs in differential diagnoses.
As pancreatic tumours with a microcystic pattern, microcystic-type SCAs with aggregates of microcysts are well known. 5, [21] [22] [23] [24] Therefore, microcystic SPNs can be confused with SCAs, particularly in limited samples such as EUS-guided needle biopsies and frozen sections. For the differential diagnosis, the identification of conventional SPNs by a careful observation of H&E staining and the immunohistochemistry of beta-catenin (nucleus + ), E-cadherin (nucleus + ) and PgR is useful (Table 2 ). Of note, we did not find that CD10 (which is known as one of the immunohistochemical markers of conventional SPNs) was useful in the present study, as microcystic areas of SPNs are CD10-negative ( Table 2 ). The significance of lower CD10 expression was uncertain, but the possibility of degeneration change was considered. Ovarian SPNs were first reported in 2010, 25 with morphological, immunohistochemical and genetic similarity to their pancreatic counterpart. Ovarian SPNs are controversial tumours in light of their possible linkage with microcystic stromal tumours (MCSTs) of the ovary in terms of similarities to CD10 and beta-catenin (nucleus + ) expression, a point mutation in exon 3 of beta-catenin (CTNNB1) gene and uniform tumour cells. 17, 26, 27 It was reported recently that MCSTs were immunohistochemically positive for FoxL2 as a sex cord marker. 28 On this point, our present findings demonstrated that FoxL2 expression was completely negative for all 44 SPNs including 13 microcystic SPNs. Our results also revealed that the microcystic SPNs showed a WT1 À /PgR + /CD56 + pattern, and these features were different from the previous report of MCSTs showing a WT1 + /PgR À /CD56 À pattern. [26] [27] [28] We therefore presume that ovarian MCSTs and microcystic SPNs are distinct entities.
In this study, most of the SPNs contained hyalinised myxoid stroma (Table 1) . We observed that the hyalinised myxoid stroma around the microcystic pattern contained abundant hyaluronan. In addition, the hyalinised myxoid stroma in the conventional areas of the microcystic SPNs and the conventional SPNs also contained abundant hyaluronan. These findings indicated that the stromal degeneration change caused by hyaluronan deposition was related to the formation of the microcystic pattern. The microcystic pattern was present in 0-4% of the total tumour area in five of the 31 conventional SPNs. The positivity of Alcian blue and that of Alcian blue after hyaluronidase digestion in the microcystic areas was similar to that of the microcystic SPNs.
In conclusion, the microcystic pattern should be recognised as part of the morphological spectrum of SPNs for the correct diagnosis of a pancreatic neoplasm with the microcystic pattern. Our present findings may contribute to the correct diagnosis of these neoplasms. Stromal change caused by an accumulation of hyaluronan may contribute to the microcystic pattern of SPN.
